Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 18/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20136985 | 0.82 | MGLL (0.62) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL20137050 | 0.81 | VEGFA (0.54) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL30476377 | 0.77 | ALDH1A1 (0.58) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL20818719 | 0.77 | ALDH1A1 (0.58) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL20137101 | 0.75 | MGLL (0.77) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL29561155 | 0.75 | MGLL (0.77) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL14847422 | 0.75 | MGLL (0.46) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL4291723 | 0.73 | NR1H2 (0.50) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL15093922 | 0.73 | MGLL (0.51) | MGLLALDH1A1VEGFAEGLN1 | |
| SCHEMBL17109170 | 0.73 | ALDH1A1 (0.58) | MGLLALDH1A1VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885ALDH1A1 4349/4885VEGFA 4885/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885ALDH1A1 4349/4885VEGFA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.